Virios Therapeutics, Inc.
VIRI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.68 | 0.13 | -1.25 |
| FCF Yield | -192.64% | -1.80% | -17.56% | -1.47% |
| EV / EBITDA | 0.00 | 1,767.30 | -4.73 | -67.20 |
| Quality | ||||
| ROIC | 0.00% | -143.08% | -167.17% | -107.75% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.71 | 0.92 | 0.94 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -180,391.22% | 57.53% | 26.91% | -302.79% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -21.98 | 0.57 | 0.90 |
| Interest Coverage | -132.63 | 0.00 | 0.00 | -2,757.57 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |